AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 283: H1455-H1461, 2002. First published June 20, 2002; doi:10.1152/ajpheart.00188.2002
0363-6135/02 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/4/H1455    most recent
00188.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selzman, C. H.
Right arrow Articles by Banerjee, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selzman, C. H.
Right arrow Articles by Banerjee, A.
Vol. 283, Issue 4, H1455-H1461, October 2002

Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation

Craig H. Selzman, Stephanie A. Miller, Michael A. Zimmerman, Fabia Gamboni-Robertson, Alden H. Harken, and Anirban Banerjee

Divison of Cardiothoracic Surgery, University of Colorado Health Sciences Center, Denver, Colorado 80262

Although monocyte chemotactic protein-1 (MCP-1) is best known for its ability to recruit mononuclear cells, few studies have examined the effects of this chemokine on other events in the vascular response to injury. The purpose of the present study was to determine the influence of MCP-1 on human vascular smooth muscle (VSMC) proliferation. MCP-1 induced concentration-dependent VSMC proliferation as measured by bromodeoxyuridine (BrdU) uptake. Direct cell counting demonstrated a twofold increase in VSMC after stimulation with MCP-1. This mitogenic effect was similar to that observed with the prototypical atherogenic cytokine platelet-derived growth factor. Immunohistochemistry and Western blot analysis revealed that MCP-1 increased both proliferating nuclear cell antigen and cyclin A expression. Whereas MCP-1 did not promote nuclear factor-kappa B activation, MCP-1-induced VSMC proliferation appeared to be dependent on phosphotidylinositol 3-kinase activation. In conclusion, MCP-1 directly induces VSMC growth, which is associated with activation of cell cycle proteins and intracellular proliferative signals. Within the inflammatory paradigm of vascular remodeling, these data suggest that MCP-1 is more than simply a chemokine but also a potent mitogen for VSMC proliferation.

chemokine; platelet-derived growth factor; proliferating cellular nuclear antigen; nuclear factor-kappa B; phosphotidylinositol 3-kinase


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
K. Egashira, K. Nakano, K. Ohtani, K. Funakoshi, G. Zhao, Y. Ihara, J.-i. Koga, S. Kimura, R. Tominaga, and K. Sunagawa
Local Delivery of Anti-Monocyte Chemoattractant Protein-1 by Gene-Eluting Stents Attenuates In-Stent Stenosis in Rabbits and Monkeys
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2563 - 2568.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. J. Haurani and P. J. Pagano
Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: Bellwether for vascular disease?
Cardiovasc Res, September 1, 2007; 75(4): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
O. Ochoa, D. Sun, S. M. Reyes-Reyna, L. L. Waite, J. E. Michalek, L. M. McManus, and P. K. Shireman
Delayed angiogenesis and VEGF production in CCR2 / mice during impaired skeletal muscle regeneration
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R651 - R661.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Schepers, D. Eefting, P.I. Bonta, J.M. Grimbergen, M.R. de Vries, V. van Weel, C.J. de Vries, K. Egashira, J.H. van Bockel, and P.H.A. Quax
Anti-MCP-1 Gene Therapy Inhibits Vascular Smooth Muscle Cells Proliferation and Attenuates Vein Graft Thickening Both In Vitro and In Vivo
Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2063 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. D. Schecter, A. B. Berman, L. Yi, H. Ma, C. M. Daly, K. Soejima, B. J. Rollins, I. F. Charo, and M. B. Taubman
MCP-1-dependent signaling in CCR2-/- aortic smooth muscle cells
J. Leukoc. Biol., June 1, 2004; 75(6): 1079 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
M.H. Tayebjee, G.Y.H. Lip, and R.J. MacFadyen
Collateralization and the response to obstruction of epicardial coronary arteries
QJM, May 1, 2004; 97(5): 259 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Parenti, L. Bellik, L. Brogelli, S. Filippi, and F. Ledda
Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells
Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1978 - H1984.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. W. Kopp, T. Holzenbein, S. Steiner, R. Marculescu, H. Bergmeister, D. Seidinger, I. Mosberger, C. Kaun, M. Cejna, R. Horvat, et al.
Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity
Blood, March 1, 2004; 103(5): 1653 - 1661.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online